{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-006004","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.054254+00:00","generated_at":"2026-05-21T08:10:31.562249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27","bullets":["Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.","Cash and investments $81.0M as of March 31, 2025; Q1 cash burn $16.9M; runway into 2026.","BLA for PRGN-2012 (RRP) under FDA priority review; PDUFA target action date August 27, 2025.","Pivotal study: 51% complete response, 86% reduction in surgeries; median follow-up 30 months.","Selected EVERSANA for commercialization support; advancing launch readiness for potential 2025 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-006004","json":"https://secwatch.observer/filing/0000950103-25-006004.json","markdown":"https://secwatch.observer/filing/0000950103-25-006004.md","text":"https://secwatch.observer/filing/0000950103-25-006004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/0000950103-25-006004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/dp228863_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:10:31.562249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}